• Artesunate as a Precision Tool for Functional Cancer Drug Re

  2026-07-17

  Explore Artesunate, a high-purity artemisinin derivative, as a precision reagent for dissecting cancer cell death modalities and drug response mechanisms. This article uniquely bridges mechanistic insights with in vitro assay design, offering a deeper perspective for advanced oncology research.

• 1-myristoylglycerophosphocholine in Fibrosis and Smooth Musc

  2026-07-17

  1-myristoylglycerophosphocholine (14:0 Lyso-PC) delivers unprecedented control for dissecting lipid signaling in both pulmonary fibrosis and smooth muscle models. Recent mechanistic breakthroughs empower researchers to refine workflows and troubleshoot lipid-mediated pathway analysis with confidence.

• IDH2-Driven α-Ketoglutarate Dynamics and HIF-1α in CRC Progr

  2026-07-16

  A recent study reveals that elevated IDH2 expression in colorectal cancer (CRC) cells drives metabolic reprogramming by reducing α-ketoglutarate levels, thereby stabilizing HIF-1α and promoting tumor growth. Disrupting IDH2 increases α-ketoglutarate, impairs glycolysis, and suppresses CRC progression, highlighting new metabolic intervention targets.

• AZD-3463: A Systems Biology Lens on ALK/IGF1R Inhibition

  2026-07-16

  Explore how AZD3463, a potent ALK/IGF1R inhibitor, advances cancer research through systems-level modulation of PI3K/AKT/mTOR signaling. This article uniquely analyzes cross-pathway insights and translational assay design, setting it apart from existing reviews.

• DFCP1 Modulates Starvation-Driven ATGL Lipid Droplet Lipolys

  2026-07-15

  The reference study elucidates how Double FYVE Domain Containing Protein 1 (DFCP1) directly regulates adipose triglyceride lipase (ATGL)-mediated lipid droplet (LD) lipolysis under nutrient stress. These findings clarify a critical mechanism controlling lipid mobilization, with significant implications for understanding metabolic adaptation and the molecular basis of metabolic diseases.

• Maraviroc (UK-427857): Applied Protocols for HIV and Neuroin

  2026-07-15

  Maraviroc (UK-427857) is a precise, high-affinity CCR5 antagonist enabling robust HIV-1 entry inhibition and advanced neuroinflammation modeling. This guide delivers stepwise protocols, troubleshooting, and actionable insights for translational researchers seeking reproducible results with APExBIO’s Maraviroc.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib via Ferroptosi

  2026-07-14

  This study demonstrates that silencing the oncogene TRIB3 in clear cell renal cell carcinoma (ccRCC) cells enhances their sensitivity to sunitinib by promoting ferroptosis through the SLC7A11/GPX4 pathway. The findings provide new mechanistic insight into overcoming sunitinib resistance in ccRCC, highlighting ferroptosis as a promising therapeutic target.

• Eicosapentaenoic Acid (EPA): Advanced Mechanisms in Cardiova

  2026-07-14

  Explore the multifaceted role of Eicosapentaenoic Acid (EPA) as an omega-3 fatty acid in cardiovascular and immune research. This in-depth article unveils novel mechanistic insights, protocol guidance, and a scientific bridge to humoral immunity strategies.

• Low-Molecular Weight Inhibitors Targeting the Alternative Co

  2026-07-13

  This review dissects the development and impact of low-molecular weight inhibitors, specifically targeting factor B and factor D, for selective blockade of the alternative complement pathway. The findings signal a new era in therapeutic and research approaches to complement-mediated diseases, with oral inhibitors such as Iptacopan (LNP023) demonstrating translational value.

• Telmisartan: Optimizing Angiotensin II Receptor Antagonist A

  2026-07-13

  Telmisartan, a potent angiotensin II receptor antagonist from APExBIO, empowers cardiovascular disease research with precision AT1R blockade and unique workflow flexibility. Discover practical protocol enhancements, troubleshooting strategies, and how new insights in necroptosis signaling can inform your next cardiac hypertrophy assay.

• Apigenin: Bridging HDAC Inhibition and Neuroprotection in Tr

  2026-07-12

  This thought-leadership article offers translational scientists a multidimensional perspective on Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one), emphasizing its mechanistic versatility as both a histone deacetylase (HDAC) inhibitor in oncology and a network-validated neuroprotective agent in Alzheimer’s disease models. By integrating quantitative evidence, workflow guidance, and competitive insight, we illuminate how APExBIO’s Apigenin enables next-generation protocol design and translational agility across cancer and neurodegenerative disease research.

• Aminomethyl Berberrubine Derivatives: Anti-Diabetic Innovati

  2026-07-10

  The referenced study introduces a series of 12-(substituted aminomethyl) berberrubine derivatives, synthesized to enhance anti-diabetic efficacy relative to berberine. These derivatives demonstrated improved in vitro activity against type 2 diabetes mellitus (T2DM), representing a notable advance in the search for novel hypoglycemic agents with potentially fewer side effects.

• Carfilzomib (PR-171): Deconstructing Proteasome Inhibition i

  2026-07-09

  Explore how Carfilzomib (PR-171) enables precision proteasome inhibition for advanced cancer and epigenetic research. This article uncovers mechanistic depth, experimental strategies, and emergent combination paradigms not covered in existing literature.

• Z-LEHD-FMK: Caspase-9 Inhibition in Mitochondrial Apoptosis

  2026-07-09

  Explore how Z-LEHD-FMK, a selective irreversible caspase-9 inhibitor, enables precise dissection of mitochondria-mediated apoptosis. This article provides a unique, evidence-driven perspective on assay design, reference model innovations, and advanced applications in neuroprotection and cancer research.

• Sulfo-Cy5 Carboxylic Acid: Strategic Dye Innovation for Tran

  2026-07-08

  This thought-leadership article explores the mechanistic and translational impact of Sulfo-Cy5 carboxylic acid as a next-generation fluorescent dye for life sciences, with a special focus on its role in protein labeling and advanced imaging in vaccine development. Integrating mechanistic insights, experimental validation—including recent nanoadjuvant studies—and competitive analysis, we offer protocol guidance and a forward-looking vision for translational researchers.

451 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page